Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental injection aims to boost platelets in chronic blood disorder

NCT ID NCT07710248

Recruiting now Disease control Sponsor: Hangzhou Sumgen Biotech Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This Phase 2 trial tests an experimental drug called SG301, given as a weekly injection, for adults with primary immune thrombocytopenia (ITP) — a condition where the immune system destroys platelets, raising bleeding risk. The study includes about 60 people who have not improved with standard treatments. Participants receive either a low or high dose of SG301 or a placebo, and researchers track safety and whether platelet counts improve.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an experimental monoclonal antibody injection called SG301
What this could lead to
If successful, SG301 could offer a new treatment option for people with chronic ITP who have not responded to standard therapies.
What could go wrong
This is an early Phase 2 trial with only 60 participants, so results may not confirm effectiveness or safety. Side effects are still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY IMMUNE THROMBOCYTOPENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune thrombocytopenic purpura primary thrombocytopenia Purpura, Thrombocytopenic, Idiopathic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY IMMUNE THROMBOCYTOPENIA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fujian Medical University Union Hospital

    RECRUITING

    Fuzhou, Fujian, 350001, China

    Contact Email: •••••@•••••

  • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences

    RECRUITING

    Tianjin, Tianjin Municipality, 300020, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Jining No.1 People's Hospital

    RECRUITING

    Jining, Shandong, 272011, China

    Contact Email: •••••@•••••

  • Pingdingshan First People's Hospital

    RECRUITING

    Pingdingshan, Henan, 467000, China

    Contact Email: •••••@•••••

  • The First Affiliated Hospital of Wenzhou Medical University

    RECRUITING

    Wenzhou, Zhejiang, 325000, China

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.